Cover Image
市場調查報告書

植物來源藥品的全球市場的預測

GLOBAL BOTANICAL & PLANT DERIVATIVE DRUG MARKET FORECAST 2018-2026

出版商 Inkwood Research 商品編碼 568466
出版日期 內容資訊 英文 160 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
植物來源藥品的全球市場的預測 GLOBAL BOTANICAL & PLANT DERIVATIVE DRUG MARKET FORECAST 2018-2026
出版日期: 2018年02月03日 內容資訊: 英文 160 Pages
簡介

本報告提供植物來源藥品的全球市場調查,市場概要,各類型、治療領域、產品、地區的市場趨勢,市場規模的預測(今後9年份),市場的促進、阻礙因素以及市場機會、課題分析,競爭情形,主要企業簡介等系統性資訊。

第1章 調查範圍

第2章 調查手法

第3章 摘要整理

  • 市場摘要
  • 主要的觀察

第4章 市場動態

  • 促進因素
  • 阻礙因素
  • 市場機會
  • 課題

第5章 市場區隔

  • 植物來源藥品的全球市場:各類型
    • 類固醇
    • 醣苷
    • 其他
  • 植物來源藥品的全球市場:各治療領域
    • 腫瘤、癌症
    • 皮膚病
    • 中樞神經疾病
    • 內分泌疾病
    • 其他
  • 植物來源藥品的全球市場:各產品
    • 局部麻醉劑
    • 咳嗽、感冒、過敏(花粉症)治療藥
    • 胃腸藥
    • 皮膚藥
    • 兒童用健康輔助食品
    • 健康輔助食品
    • 營養強壯劑

第6章 市場分析

  • 製造流程
  • 價值鏈分析
  • 政策、法律規章的指南
  • 波特的五力分析
  • 主要的購買標準

第7章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • 其他
  • 其他地區
    • 南美
    • 中東、非洲

第8章 競爭情形

  • 主要策略
    • 合併、收購
    • 夥伴關係、合作
    • 投資、產業擴大
  • 市場佔有率分析
  • 主要企業分析

第9章 企業簡介

  • ABBOTT LABORATORIES
  • BAYER HEALTHCARE LLC
  • BIONOVA
  • BRISTOL-MYERS SQUIBB
  • CURA PHARM
  • ELI LILLY AND COMPANY
  • GLAXOSMITHKLINE
  • GLENMARK PHARMACEUTICALS LTD.
  • LUPIN LTD
  • MEDIGENE
  • NOVARTIS INTERNATIONAL AG
  • PFIZER
  • PIRAMAL PHYTOCARE LTD.
  • RANBAXY LABORATORIES LTD
  • TASLY PHARMACEUTICALS INC.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 10671

KEY FINDINGS

The Global Botanical and plant-derivative drug market was estimated to be worth $ 26621 million in 2017. Due to the growing application of these drugs in several diseases, the market is expected to witness a rise in CAGR of 8.58% for the forecast years of 2018-2026 and is predicted to reach a worth of $53850 million by its end.

MARKET INSIGHTS

The global botanical and plant-derivative drug market is segmented on the basis of types, products and therapeutic applications. The type segment of the market includes steroids, terpenes, phenols glycosides, and other types. The product segment of this market includes herbal/traditional cough, cold and allergy (hay fever) remedies, herbal/traditional topical analgesics, herbal/traditional digestive remedies, herbal/traditional pediatric dietary supplements, herbal/traditional dermatological, herbal/traditional tonics and herbal/traditional dietary supplements. The therapeutic applications of this market can be found in dermatology, oncology, hormone disease, CNS disorders and in other therapeutic applications.

REGIONAL INSIGHTS

Geographical segmentation of the market is done into Europe, North America, Asia-Pacific and rest of world. The APAC market is expected to dominate the global scene throughout the forecast period, followed by Europe and North America. A major contribution to the APAC market comes from India, where 80% rural populations still use the indigenous systems of medicines and medical herbs. Botanical Plant derivative drug market in Europe is mainly driven by rising adoption of traditional and plant-based medicines and growing investments in R&D for the field of botanical medicines, whereas superior government efforts targeted towards growing the use of botanical drugs approved by FDA and the NIH's (National Institutes of Health) Botanical Research Centers Program are expected to boost the North America botanical & plant derivative drug market growth.

COMPETITIVE INSIGHTS

Some of the renowned companies engaged in this market are Analyticon Discovery Gmbh, Abbott Laboratories, Bayer Healthcare Llc, Bionova, Boehringer Ingelheim, Bristol-Myers Squibb, Dr Willmar Schwabe Gmbh & Co. Kg, Cura Pharm, Eli Lilly And Company, Glenmark Pharmaceuticals Ltd, GlaxoSmithKline, Indena Viale Ortles, Medigene, Lupin Ltd, Novartis International Ag, Piramal Phytocare Ltd, Pfizer, Ranbaxy Laboratories Ltd (Acquired By Sun Pharmaceuticals Ltd), Tasly Pharmaceuticals Inc and Sanofi.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. ASIA PACIFIC LEADS THE GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET
    • 3.2.2. INDIA BOTANICAL AND PLANT DERIVATIVE DRUGS MARKET TO OFFER GREAT OPPORTUNITIES
    • 3.2.3. GLYCOSIDES IS A QUICKLY RISING MARKET IN TERMS OF TYPES
    • 3.2.4. ONCOLOGY HOLDS THE LARGEST MARKET SHARE IN TERMS OF THERAPEUTIC APPLICATION
    • 3.2.5. HERBAL/TRADITIONAL TOPICAL ANALGESICS PRODUCT DEMAND IS GROWING RAPIDLY

4. MARKET DYNAMICS

  • 4.1. DRIVERS
    • 4.1.1. GROWING APPLICATIONS IN DISEASES
    • 4.1.2. GROWING FDA APPROVALS
    • 4.1.3. TECHNOLOGICAL DEVELOPMENT IN THE MANUFACTURING PROCESS
    • 4.1.4. RISING DEMAND FOR TRADITIONAL MEDICINES
    • 4.1.5. GROWING FOCUS TOWARDS NATURAL SOURCE MEDICINES
  • 4.2. RESTRAINTS
    • 4.2.1. STRINGENT REGULATIONS REGARDING THE USE AND APPROVAL OF BOTANICAL DRUGS
    • 4.2.2. LIMITED ADOPTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
  • 4.3. OPPORTUNITIES
    • 4.3.1. RISING FDA APPROVALS FOR BOTANICAL DRUGS
    • 4.3.2. ESCALATING USE OF BOTANICAL DRUGS
    • 4.3.3. INCREASING INVESTMENT IN ASIA PACIFIC
  • 4.4. CHALLENGES
    • 4.4.1. PRESENCE OF SUBSTITUTES FOR BOTANICAL & PLANT DERIVATIVE DRUG
    • 4.4.2. TOXICITY RELATED ISSUES AND SAFETY CONCERNS

5. MARKET SEGMENTATION

  • 5.1. MARKET BY TYPES 2018-2026
    • 5.1.1. TERPENES
    • 5.1.2. STEROIDS
    • 5.1.3. GLYCOSIDES
    • 5.1.4. PHENOLS
    • 5.1.5. OTHER TYPES
  • 5.2. MARKET BY THERAPEUTIC APPLICATIONS 2018-2026
    • 5.2.1. ONCOLOGY
    • 5.2.2. DERMATOLOGY
    • 5.2.3. CNS DISORDERS
    • 5.2.4. HORMONE DISEASES
    • 5.2.5. OTHER THERAPEUTIC APPLICATIONS
  • 5.3. MARKET BY PRODUCTS 2018-2026
    • 5.3.1. HERBAL/TRADITIONAL TOPICAL ANALGESICS
    • 5.3.2. HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES
    • 5.3.3. HERBAL/TRADITIONAL DIGESTIVE REMEDIES
    • 5.3.4. HERBAL/TRADITIONAL DERMATOLOGICAL
    • 5.3.5. HERBAL/TRADITIONAL PEDIATRIC DIETARY SUPPLEMENTS
    • 5.3.6. HERBAL/TRADITIONAL DIETARY SUPPLEMENTS
    • 5.3.7. HERBAL/TRADITIONAL TONICS

6. KEY ANALYTICS

  • 6.1. MANUFACTURING PROCESS
  • 6.2. VALUE CHAIN ANALYSIS
  • 6.3. LEGAL, POLICY AND REGULATORY FRAMEWORK
  • 6.4. PORTER'S FIVE FORCES ANALYSIS
    • 6.4.1. THREAT OF NEW ENTRANTS
    • 6.4.2. THREATS OF SUBSTITUTE PRODUCT
    • 6.4.3. BARGAINING POWER OF BUYER
    • 6.4.4. BARGAINING POWER OF SUPPLIER
    • 6.4.5. INTENSITY OF COMPETITIVE RIVALRY
  • 6.5. KEY BUYING CRITERIA

7. GEOGRAPHIC ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. UNITED KINGDOM
    • 7.2.2. FRANCE
    • 7.2.3. GERMANY
    • 7.2.4. SPAIN
    • 7.2.5. ITALY
    • 7.2.6. REST OF EUROPE
  • 7.3. ASIA-PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. INDIA
    • 7.3.3. JAPAN
    • 7.3.4. AUSTRALIA
    • 7.3.5. SOUTH KOREA
    • 7.3.6. REST OF ASIA-PACIFIC
  • 7.4. REST OF WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST & AFRICA

8. COMPETITIVE LANDSCAPE

  • 8.1. KEY STRATEGIES
    • 8.1.1. MERGER & ACQUISITION
    • 8.1.2. PARTNERSHIP & COLLABORATION
    • 8.1.3. EXPANSION & INVESTMENT
  • 8.2. MARKET SHARE ANALYSIS
  • 8.3. KEY COMPANIES ANALYSIS

9. COMPANY PROFILE

  • 9.1. ABBOTT LABORATORIES
    • 9.1.1. OVERVIEW
    • 9.1.2. PRODUCT PORTFOLIO
    • 9.1.3. STRATEGIC INITIATIVES
    • 9.1.4. SCOT ANALYSIS
  • 9.2. ANALYTICON DISCOVERY GMBH
    • 9.2.1. OVERVIEW
    • 9.2.2. PRODUCT PORTFOLIO
    • 9.2.3. STRATEGIC INITIATIVE
    • 9.2.4. SCOT ANALYSIS
  • 9.3. BAYER HEALTHCARE LLC
    • 9.3.1. OVERVIEW
    • 9.3.2. PRODUCT PORTFOLIO
    • 9.3.3. SCOT ANALYSIS
  • 9.4. BOEHRINGER INGELHEIM
    • 9.4.1. OVERVIEW
    • 9.4.2. PRODUCT PORTFOLIO
    • 9.4.3. STRATEGIC INITIATIVE
    • 9.4.4. SCOT ANALYSIS
  • 9.5. BIONOVA
    • 9.5.1. OVERVIEW
    • 9.5.2. PRODUCT PORTFOLIO
    • 9.5.3. SCOT ANALYSIS
  • 9.6. BRISTOL-MYERS SQUIBB
    • 9.6.1. OVERVIEW
    • 9.6.2. STRATEGIC INITIATIVE
    • 9.6.3. SCOT ANALYSIS
  • 9.7. CURA PHARM
    • 9.7.1. OVERVIEW
    • 9.7.2. PRODUCT PORTFOLIO
    • 9.7.3. SCOT ANALYSIS
  • 9.8. DR. WILLMAR SCHWABE GMBH & CO. KG
    • 9.8.1. OVERVIEW
    • 9.8.2. PRODUCT PORTFOLIO
    • 9.8.3. SCOT ANALYSIS
  • 9.9. ELI LILLY AND COMPANY
    • 9.9.1. OVERVIEW
    • 9.9.2. PRODUCT PORTFOLIO
    • 9.9.3. SCOT ANALYSIS
  • 9.10. GLAXOSMITHKLINE
    • 9.10.1. OVERVIEW
    • 9.10.2. PRODUCT PORTFOLIO
    • 9.10.3. STRATEGIC INITIATIVES
    • 9.10.4. SCOT ANALYSIS
  • 9.11. GLENMARK PHARMACEUTICALS LTD.
    • 9.11.1. OVERVIEW
    • 9.11.2. PRODUCT PORTFOLIO
    • 9.11.3. STRATEGIC INITIATIVE
    • 9.11.4. SCOT ANALYSIS
  • 9.12. INDENA VIALE ORTLES
    • 9.12.1. OVERVIEW
    • 9.12.2. PRODUCT PORTFOLIO
    • 9.12.3. STRATEGIC INITIATIVE
    • 9.12.4. SCOT ANALYSIS
  • 9.13. LUPIN LTD
    • 9.13.1. OVERVIEW
    • 9.13.2. PRODUCT PORTFOLIO
    • 9.13.3. STRATEGIC INITIATIVE
    • 9.13.4. SCOT ANALYSIS
  • 9.14. MEDIGENE
    • 9.14.1. OVERVIEW
    • 9.14.2. PRODUCT PORTFOLIO
    • 9.14.3. STRATEGIC INITIATIVES
    • 9.14.4. SCOT ANALYSIS
  • 9.15. NOVARTIS INTERNATIONAL AG
    • 9.15.1. OVERVIEW
    • 9.15.2. PRODUCT PORTFOLIO
    • 9.15.3. STRATEGIC INITIATIVES
    • 9.15.4. SCOT ANALYSIS
  • 9.16. PFIZER
    • 9.16.1. OVERVIEW
    • 9.16.2. PRODUCT PORTFOLIO
    • 9.16.3. STRATEGIC INITIATIVE
    • 9.16.4. SCOT ANALYSIS
  • 9.17. PIRAMAL PHYTOCARE LTD.
    • 9.17.1. OVERVIEW
    • 9.17.2. PRODUCT PORTFOLIO
    • 9.17.3. STRATEGIC INITIATIVE
    • 9.17.4. SCOT ANALYSIS
  • 9.18. RANBAXY LABORATORIES LTD (ACQUIRED BY SUN PHARMACEUTICALS LTD)
    • 9.18.1. OVERVIEW
    • 9.18.2. PRODUCTION PORTFOLIO
    • 9.18.3. STRATEGIC INITIATIVE-
    • 9.18.4. SCOT ANALYSIS
  • 9.19. SANOFI
    • 9.19.1. OVERVIEW
    • 9.19.2. PRODUCT PORTFOLIO
    • 9.19.3. STRATEGIC INITIATIVE
    • 9.19.4. SCOT ANALYSIS
  • 9.20. TASLY PHARMACEUTICALS INC.
    • 9.20.1. OVERVIEW
    • 9.20.2. PRODUCTION PORTFOLIO
    • 9.20.3. SCOT ANALYSIS

TABLE LIST

  • TABLE 1 GLOBAL BOTANICAL & PLANT DERIVATIVE DRUG MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 2 GLOBAL BOTANICAL & PLANT DERIVATIVE DRUG MARKET, BY TYPES 2018-2026 ($ MILLION)
  • TABLE 3 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 4 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 5 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 6 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 7 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2018-2026 ($ MILLION)
  • TABLE 8 GLOBAL BOTANICAL & PLANT DERIVATIVE DRUG MARKET BY THERAPEUTIC APPLICATIONS 2018-2026 ($ MILLION)
  • TABLE 9 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 10 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 11 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 12 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 13 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 14 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET, BY PRODUCT 2018-2026 ($ MILLION)
  • TABLE 15 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 16 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 17 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 18 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 19 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 20 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 21 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS, BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 22 GLOBAL BOTANICAL & PLANT DERIVATIVE DRUG MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 23 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • TABLE 24 EUROPE BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • TABLE 25 ASIA-PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • TABLE 26 REST OF WORLD BOTANICAL AND PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE LIST
  • FIGURE 1 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 2 INDIA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 3 GLOBAL BOTANICAL & PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2018-2026 ($ MILLION)
  • FIGURE 4 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES 2018-2026 ($ MILLION)
  • FIGURE 5 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2018-2026 ($ MILLION)
  • FIGURE 6 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2018-2026 ($ MILLION)
  • FIGURE 7 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS 2018-2026 ($ MILLION)
  • FIGURE 8 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2018-2026 ($ MILLION)
  • FIGURE 9 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY 2018-2026 ($ MILLION)
  • FIGURE 10 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY 2018-2026 ($ MILLION)
  • FIGURE 11 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS 2018-2026 ($ MILLION)
  • FIGURE 12 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE 2018-2026 ($ MILLION)
  • FIGURE 13 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2018-2026 ($ MILLION)
  • FIGURE 14 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS 2018-2026 ($ MILLION)
  • FIGURE 15 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES 2018-2026 ($ MILLION)
  • FIGURE 16 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES 2018-2026 ($ MILLION)
  • FIGURE 17 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS 2018-2026 ($ MILLION)
  • FIGURE 18 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS 2018-2026 ($ MILLION)
  • FIGURE 19 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS 2018-2026 ($ MILLION)
  • FIGURE 20 GLOBAL BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS 2018-2026 ($ MILLION)
  • FIGURE 21 EVOLUTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
  • FIGURE 22 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 23 UNITED STATES BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 24 CANADA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 25 UNITED KINGDOM BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 26 FRANCE BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 27 GERMANY BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 28 SPAIN BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 29 ITALY BOTANICAL PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 30 REST OF EUROPE BOTANICAL &PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 31 CHINA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 32 INDIA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 33 JAPAN BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 34 AUSTRALIA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 35 SOUTH KOREA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 36 REST OF ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 37 LATIN AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 38 MIDDLE EAST & AFRICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
  • FIGURE 39 GLOBAL BOTANICAL & PLANT DERIVATIVE DRUG MARKET SHARE 2016
Back to Top